Tempus AI, Inc. · Healthcare · Health Information Services
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$53.23
−$2.18 (−3.93%) 4:00 PM ET
After hours$52.89
−$0.34 (−0.64%) 6:40 PM ET
Prev closePrevC$55.41
OpenOpen$53.93
Day highHigh$54.34
Day lowLow$52.29
VolumeVol4,312,697
Avg volAvgVol5,745,414
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$9.52B
P/E ratio
-37.49
FY Revenue
$1.27B
EPS
-1.42
Gross Margin
62.74%
Sector
Healthcare
AI report sections
MIXED
TEM
Tempus AI, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−15% (Below avg)
Vol/Avg: 0.85×
RSI
44.33(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.01 (Strong)
MACD: 0.19 Signal: 0.18
Short-Term
+0.48 (Strong)
MACD: -2.04 Signal: -2.52
Long-Term
+0.24 (Strong)
MACD: -4.30 Signal: -4.54
Intraday trend score
53.00
LOW39.00HIGH53.00
Latest news
TEM•12 articles•Positive: 11Neutral: 1Negative: 0
PositiveBenzinga• Lekha Gupta
Consumer Tech News (Feb 23-27): US–Taiwan Trade Tensions Escalates, Amazon Invests $12B In US & More
The week saw escalating US-Taiwan trade tensions following the Supreme Court's strike-down of Trump's emergency tariff authority, prompting new tariff rollouts. Major tech companies reported mixed earnings results, with Amazon announcing a $12B US investment and Apple shifting Mac Mini production to Texas. AI developments dominated headlines with OpenAI's Frontier Alliances program, Microsoft's Sovereign Cloud expansion, and concerns over Chinese AI capabilities. The EV market showed growth with new models from Tesla competitors, while several companies announced restructuring efforts.
Revenue of $367.21M beat Street estimate of $362.29M, though losses of 4 cents per share were in line with consensus.
PositiveThe Motley Fool• Rick Munarriz
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood's Ark Invest added to positions in AMD, Tesla, and Tempus AI on Wednesday amid market volatility. AMD delivered strong earnings with 34% revenue growth and beat profit expectations, but shares fell 17% due to disappointing guidance. Tesla is pivoting toward robotics production as EV sales stall. Tempus AI, focused on oncology AI solutions, has seen shares cut in half from October highs despite 84% revenue growth.
Explosive 84% revenue growth through first nine months of year with strong market penetration (65% of U.S. academic medical centers, 55% of oncologists connected). Despite 50% decline from October highs, fundamentals show robust adoption and growth in AI-driven oncology solutions.
PositiveGlobeNewswire Inc.• Towards Healthcare
Real-World Data on Healthcare Technology Adoption: Company Insights and Government Trends with Key Statistics (e.g., 71% U.S. Hospitals Adoption, $3B Company Valuations)
U.S. hospitals are rapidly adopting AI and healthcare technology, with 71% now using predictive AI as of 2024, up from 66% in 2023. Leading healthcare tech companies like Tempus AI, OpenEvidence, Sword Health, and Huma are securing significant funding and valuations, while clinical documentation automation has reached 100% adoption in surveyed U.S. health systems. The global AI in healthcare market is projected to grow from $37.98 billion in 2025 to $928.18 billion by 2035 at a CAGR of 37.66%.
Company demonstrates strong growth with 2,300 employees, successful Nasdaq IPO, and significant acquisition spending ($600M for Ambry Genetics), indicating robust market position and expansion strategy in precision medicine.
PositiveThe Motley Fool• Beth Mckenna
Here Are Congresswoman Nancy Pelosi's Initial Stock Moves in 2026: They Include Nvidia, Alphabet, and Amazon Stocks, and Others
Nancy Pelosi and her husband Paul filed their first 2026 financial disclosures, revealing bullish stock moves in major tech companies including Nvidia, Alphabet, and Amazon through exercised call options. Their portfolio of five stocks achieved approximately 41.7% returns over one year, double the S&P 500 performance, demonstrating their successful long-term investing track record focused on AI and technology sectors.
Pelosi exercised 50 call options to purchase 5,000 shares at $20 strike price, indicating bullish bet on AI-driven precision medicine company aligned with broader AI growth theme.
Esoteric Testing Research Report 2026 - Global $41.5+ Bn Market Trends, Opportunities, and Forecasts to 2031
The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.
Genomics revenue reached $451.7 million in 2024, a 24.4% year-over-year increase, reflecting growing dependence on AI-driven platforms for precision diagnostic data interpretation.
PositiveBenzinga• Vishaal Sanjay
Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning?
Ark Invest unveiled its 'big ideas' for 2026 through cryptic ARKmoji images, challenging users to interpret six investment themes: AI Agents, Genomics, Space Race (reusable rockets), Cryptocurrencies/Tokenization, Robotics, and The Great Acceleration. The firm highlighted portfolio holdings aligned with each theme, spanning multiple sectors from biotech to defense and space technology.
Featured as a key agentic AI holding, matching Ark's identified big idea for AI Agents in 2026.
PositiveInvesting.com• Jesse Cohen
4 Hyper-Growth Stocks Ready to Dazzle This Earnings Season
Four high-growth stocks are positioned to deliver explosive earnings growth this season: Robinhood (HOOD) with 51.1% EPS growth expected, Reddit (RDDT) with 240.4% EPS growth, IREN with 104.8% revenue growth, and Tempus AI (TEM) with 80.1% revenue growth. All four companies are benefiting from strong industry tailwinds including AI adoption, crypto trading expansion, and healthcare innovation.
Expected 80.1% revenue growth with 105% stock rally in 2025. Leading AI-powered precision medicine with expanding pharma partnerships and FDA clearances. Analysts see 69% upside to $87.92 target despite current losses, reflecting growth potential.
PositiveThe Motley Fool• Joe Tenebruso
Why Tempus AI Stock Rose Today
Tempus AI stock rose over 4% after issuing an upbeat sales forecast, projecting 83% year-over-year revenue growth to $1.27 billion for the full year. The healthcare AI company announced record contract value of $1.1 billion and a net revenue retention of 126%, driven by strong diagnostics sales growth of 121% and partnerships with major pharmaceutical companies including Pfizer, Novartis, and Eli Lilly.
Strong upbeat sales forecast with 83% YoY revenue growth, record contract value of $1.1 billion, impressive net revenue retention of 126%, and accelerating diagnostics sales of 121%. Stock rose 4% on the announcement.
PositiveBenzinga• Lekha Gupta
Why Tempus AI Stock Is Trading Higher On Monday?
Tempus AI (NASDAQ: TEM) stock rose on Monday following the release of preliminary fourth-quarter and full-year 2025 results showing $1.27 billion in revenue with 83% year-over-year growth. The company also announced two major strategic partnerships: a multi-year collaboration with NYU Langone Health to advance cancer care through molecular profiling, and a contract with Northwestern Medicine to broaden access to genomic testing for cancer patients.
TEMTempus AIcancer testinggenomic testingrevenue growthstrategic partnershipNYU Langone HealthNorthwestern Medicine
Sentiment note
Strong financial results with 83% YoY revenue growth to $1.27 billion, significant organic growth of 30%, and two major strategic partnerships with leading healthcare institutions that expand market reach and validate the company's cancer testing capabilities. Stock price increased 3.86% on the announcement.
PositiveBenzinga• Rishabh Mishra
Stock Market Today: Dow Jones, S&P 500 Futures Tumble As DOJ Serves Federal Reserve—Vistra, Tempus AI, Alibaba In Focus
U.S. stock futures declined on Monday following tensions between the DOJ and Federal Reserve over Chair Powell's congressional testimony. Major indices fell 0.57-1.04% in premarket trading. Key movers included Vistra (up on Meta nuclear deal), Alibaba (up on AI milestone), Tempus AI (up on strong 2025 results), and XPeng (up on delivery growth). The market awaits key economic data this week including CPI and jobless claims.
VSTBABATEMXPEVstock marketfutures declineDOJ Federal Reservenuclear power deal
Sentiment note
Stock jumped 10.7% after reporting record $1.1 billion in total contract value and 126% net revenue retention for 2025, showing exceptional business growth and client expansion.
PositiveInvesting.com• Jesse Cohen
Q4 Earnings Preview: Wall Street’s Make-or-Break Moment as Reporting Season Looms
Wall Street's Q4 2025 earnings season begins with major banks like JPMorgan Chase, Citigroup, and Wells Fargo leading the way. The S&P 500 sits near all-time highs at 6,921, with analysts expecting 8.3% year-over-year EPS growth and 7.6% revenue growth. The Technology sector is expected to outperform with 25.7% EPS growth driven by AI and semiconductors, while forward P/E ratios at 21.8 suggest stretched valuations that could amplify market reactions to earnings beats or misses.
Tech company forecast to deliver 50%+ growth in both EPS and revenue; AI-focused company
NeutralThe Motley Fool• David Jagielski
Is Tempus AI the Next Big Artificial Intelligence Stock to Buy?
Tempus AI is a healthcare AI company with over 400 petabytes of medical data and partnerships with top oncology companies. Despite strong revenue growth of 85%, the company continues to struggle with profitability and high cash burn, making it a risky investment.
TEMAIhealthcaregenomicsdata servicesoncology
Sentiment note
The company shows promising growth in revenue (85% year-over-year) and has a substantial healthcare data set, but significant concerns exist around ongoing operating losses and high cash burn, which prevent a fully positive outlook
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal